Results
Filtros
Why does cannabis treatment need to be personalized?
Deusa Cast episode addresses safety, oversight, and the role of compounding pharmacy in building personalized treatments, including medical cannabis
Medical Cannabis: Brazil as a Global Reference
Regulatory advances and scientific potential put the country on the radar of international investors and consolidate the veterinary sector
Purple and Orange February raises awareness for Alzheimer's, Lupus, Fibromyalgia, and Leukemia; see advances in medical cannabis care
Campaign reinforces the importance of early diagnosis and points to medical cannabis as an ally in symptom management and quality of life for patients
Review of RDC 660 reignites debate on competitiveness and access to imported products
Anvisa proposes exclusive process for the regulation and experts point out impact on the sector
Argentinian Government Adjusts Institutional Management of Medicinal Cannabis Without Changing the Law
Argentinian government decrees promote administrative changes in the state structure, keeping the legislation on medicinal cannabis in the country in force
Placebo-Controlled Study Shows Greater Efficacy of Cannabis in Treating Migraine
A double-blind, placebo-controlled clinical trial evaluated different formulations of vaporized cannabis for the acute treatment of migraine.
How to Prevent Dogs and Cats from Chewing on Cannabis Plants at Home
Expert explains why dogs and cats may be interested in plants and provides simple measures to prevent ingestion and preserve animal safety
CIOSP discusses advancement of cannabinoid therapies in dentistry after Anvisa update
The topic was discussed during a lecture at the 43rd CIOSP, the largest dentistry congress in Latin America, focusing on scientific evidence and the impacts of Anvisa's new regulations on dental practice in the treatment of orofacial pain.
Federal reclassification of cannabis in the US focuses on medicinal use
The change in federal legislation recognizes the medical use of cannabis, but does not alter the rules for recreational consumption or the national prohibition
Cannabis Shelf Life: Importance of Storage in Therapeutic Properties
Preservation of cannabinoids and treatment effectiveness directly depend on strict control of light and humidity
Book reveals the therapeutic power of cannabis and reinforces Portugal as a global hub in the sector
Work brings together science, real stories, and regulatory experience to demystify medicinal cannabis
Cannabis Fair 2026 solidifies Brazil as a global powerhouse and attracts the attention of major investors
Cannabis Fair 2026, taking place from May 21 to 23 in São Paulo, will bring together companies, researchers, and investors, highlighting the industrial, technological, and regulatory advancements of cannabis in Brazil
Pharmacists Appeal to Supreme Court and Question Hospital Model for Medicinal Cannabis in Spain
Pharmaceutical entities challenge in the Supreme Court the exclusivity of hospitals in dispensing magistral formulas based on medicinal cannabis, as provided in a recent decree
Anvisa approves resolutions to regulate cannabis cultivation in Brazil
Agency defines a modular strategy for cannabis cultivation, establishing distinct rules for patient associations, research, and industry
Anvisa approves new Cannabis regulation and allows compounding pharmacies
Revision of RDC 327 allows the compounding sector to produce derivatives, while individual importation by individuals remains under old rules and will be analyzed separately
Anvisa proposes new RDC for medicinal cannabis products and maintains RDC 660 out of the review
Anvisa's proposal establishes a new regulatory framework for industrialized medicinal cannabis products in Brazil
Follow Live: Anvisa now debates review of RDC 327 and cultivation
Anvisa directors meet this Wednesday (28) to discuss the update of medicinal cannabis regulations; learn how to follow
Follow Live: Anvisa now debates revision of RDC 327 and cultivation
Anvisa directors meet this Wednesday (28) to discuss the update of medicinal cannabis regulations; learn how to follow
Anvisa presents rules for commercial cultivation of cannabis maintaining low THC content for the pharmaceutical industry
Proposal authorizes companies to cultivate plants with up to 0.3% THC exclusively for the production of medicinal inputs, but experts warn of the technical unfeasibility of the limit in a tropical climate
Medical cannabis and compounding pharmacies: Anfarmag's position
In Deusa Cast #54, Marco Fiaschetti advocates for treatment customization and the inclusion of the compounding model in the revision of RDC 327